Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy
Joint Authors
Osaka, Kimito
Makiyama, Kazuhide
Miyamoto, Hiroshi
Miyoshi, Yasuhide
Teranishi, Jun-ichi
Yao, Masahiro
Uemura, Hiroji
Ohtake, Shinji
Kasahara, Ryo
Hattori, Yusuke
Mizuno, Nobuhiko
Umemoto, Susumu
Nakaigawa, Noboru
Ito, Hiroki
Kawahara, Takashi
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-09-08
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Introduction and Objectives.
Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients.
We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy.
In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy.
Methods.
A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study.
The cut-off point of NLR according to the sensitivity and specificity levels was derived from the area under receiver operator characteristics (AUROC) curve plotted for disease progression or overall mortality.
Results.
The NLR cut-off point was determined as 4.14 for both tumor progression and overall mortality.
Median progression-free survival (PFS)/overall survival (OS) in the higher NLR group (NLR ≥ 4.14) and lower NLR group (NLR < 4.14) were 194/468 days versus 73/237 days, respectively.
Kaplan-Meier analysis showed that higher NLR significantly correlated with poorer PFS (p=0.011) and OS (p=0.045).
Conclusions.
NLR may serve as a new biomarker to predict responses to GN-based chemotherapy in advanced bladder cancer patients and/or their prognosis.
American Psychological Association (APA)
Ohtake, Shinji& Kawahara, Takashi& Kasahara, Ryo& Ito, Hiroki& Osaka, Kimito& Hattori, Yusuke…[et al.]. 2016. Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International،Vol. 2016, no. 2016, pp.1-5.
https://search.emarefa.net/detail/BIM-1099416
Modern Language Association (MLA)
Ohtake, Shinji…[et al.]. Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International No. 2016 (2016), pp.1-5.
https://search.emarefa.net/detail/BIM-1099416
American Medical Association (AMA)
Ohtake, Shinji& Kawahara, Takashi& Kasahara, Ryo& Ito, Hiroki& Osaka, Kimito& Hattori, Yusuke…[et al.]. Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. BioMed Research International. 2016. Vol. 2016, no. 2016, pp.1-5.
https://search.emarefa.net/detail/BIM-1099416
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1099416